Another human study was part of a cardiac safety study where rosiglitazone 4 mg b.i.d. was compared to glyburide in 121 patients for 52 weeks [32]. After 28 weeks of treatment, both groups had significant reductions in ACR of about 30%, but after 52 weeks only rosiglitazone group continued to demonstrate a significant ACR reduction. This finding suggests that duration of follow-up is an important variable in assessing the effect of TZDs [32].